DK8889A - Phosphorholdige squalen-synthetase-inhibitorer, deres fremstilling og anvendelse, samt mellemprodukter og fremstilling deraf - Google Patents

Phosphorholdige squalen-synthetase-inhibitorer, deres fremstilling og anvendelse, samt mellemprodukter og fremstilling deraf

Info

Publication number
DK8889A
DK8889A DK008889A DK8889A DK8889A DK 8889 A DK8889 A DK 8889A DK 008889 A DK008889 A DK 008889A DK 8889 A DK8889 A DK 8889A DK 8889 A DK8889 A DK 8889A
Authority
DK
Denmark
Prior art keywords
preparation
squalen
intermediates
phosphorus
synthetase inhibitors
Prior art date
Application number
DK008889A
Other languages
English (en)
Other versions
DK8889D0 (da
Inventor
Scott A Biller
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of DK8889D0 publication Critical patent/DK8889D0/da
Publication of DK8889A publication Critical patent/DK8889A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/42—Halides thereof
    • C07F9/425—Acid or estermonohalides thereof, e.g. RP(=X)(YR)(Hal) (X, Y = O, S; R = H, or hydrocarbon group)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK008889A 1988-01-11 1989-01-10 Phosphorholdige squalen-synthetase-inhibitorer, deres fremstilling og anvendelse, samt mellemprodukter og fremstilling deraf DK8889A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/141,744 US4871721A (en) 1988-01-11 1988-01-11 Phosphorus-containing squalene synthetase inhibitors

Publications (2)

Publication Number Publication Date
DK8889D0 DK8889D0 (da) 1989-01-10
DK8889A true DK8889A (da) 1989-07-12

Family

ID=22497032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK008889A DK8889A (da) 1988-01-11 1989-01-10 Phosphorholdige squalen-synthetase-inhibitorer, deres fremstilling og anvendelse, samt mellemprodukter og fremstilling deraf

Country Status (8)

Country Link
US (1) US4871721A (da)
EP (1) EP0324421A3 (da)
JP (1) JPH01213288A (da)
AU (1) AU615507B2 (da)
DK (1) DK8889A (da)
HU (1) HU203894B (da)
NZ (1) NZ227303A (da)
ZA (1) ZA8953B (da)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4682645A (en) * 1986-03-03 1987-07-28 Olin Corporation Control system for electromagnetic casting of metals
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
US5212164A (en) * 1988-08-29 1993-05-18 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
EP0356866A3 (en) * 1988-08-29 1991-03-27 E.R. SQUIBB & SONS, INC. Phosphorus-containing squalene synthetase inhibitors and method
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2007641A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) * 1989-07-17 1991-01-17 Scott Adams Biller Phosphorus-containing squalene synthetase inhibitors and method
US5055487A (en) * 1990-03-21 1991-10-08 Merck & Co., Inc. Novel anti-fungal compounds
IL97251A0 (en) * 1990-03-21 1992-05-25 Merck & Co Inc Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them
US5132320A (en) * 1990-03-21 1992-07-21 Merck & Co., Inc. Squalene synthetase inhibitors
US5096923A (en) * 1990-03-21 1992-03-17 Merck & Co., Inc. Novel squalene synthetase inhibitors
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US6630502B2 (en) 1990-05-15 2003-10-07 E.R. Squibb & Sons, Inc. Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5102907A (en) * 1990-09-13 1992-04-07 Merck & Co., Inc. Novel squalene synthetase inhibitors
US5026554A (en) * 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
CA2067974A1 (en) * 1991-05-13 1992-11-14 Scott A. Biller Method for lowering cholesterol employing a phosphonomethylphosphinate squalene synthetase inhibitor
US5364948A (en) * 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
EP0526936A3 (en) 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
JPH05239075A (ja) * 1991-08-27 1993-09-17 Eisai Co Ltd 含リンイソプレノイド誘導体
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
ES2133278T3 (es) * 1991-10-07 1999-09-16 Tno Uso de analogos de pirofosfato de poliisoprenilo para inhibir la isoprenilacion de proteinas.
ATE126059T1 (de) * 1991-10-11 1995-08-15 Squibb & Sons Inc Verwendung von farnesyl-protein transferaseinhibitoren zur herstellung eines arzneimittels zur blockierung von durch ras- oncogenen hervorgerufenen neoplastischen transformationen von zellen.
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5200554A (en) * 1992-01-21 1993-04-06 Nasman Jan Anders H Bisphosphonic acid derivatives and their use
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
US5283256A (en) * 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5254544A (en) * 1992-09-25 1993-10-19 E. R. Squibb & Sons, Inc. Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
US5332728A (en) * 1992-11-23 1994-07-26 Bristol-Myers Squibb Company Method for treating a fungal infection
US5362752A (en) * 1993-05-17 1994-11-08 Merck & Co., Inc. Chemical compounds
US5712261A (en) * 1993-10-04 1998-01-27 Magnin; David R. Method for preventing or treating hypertriglyceridemia
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5843983A (en) * 1996-02-15 1998-12-01 Sankyo Company, Limited Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
US20020086380A1 (en) * 1996-03-29 2002-07-04 Francis X. Cunningham Jr Genes encoding epsilon lycopene cyclase and method for producing bicyclic carotene
WO1998006705A1 (en) * 1996-08-14 1998-02-19 Zeneca Limited Substituted pyrimidine derivatives and their pharmaceutical use
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
JP2001511799A (ja) 1997-02-13 2001-08-14 ゼネカ・リミテッド オキシド−スクアレンシクラーゼ阻害剤として有用なヘテロ環式化合物
WO1998035956A1 (en) 1997-02-13 1998-08-20 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
US6531303B1 (en) 1998-07-06 2003-03-11 Arkion Life Sciences Llc Method of producing geranylgeraniol
ATE490332T1 (de) 1998-07-06 2010-12-15 Dcv Inc Verfahren zur vitaminherstellung
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US20040249219A1 (en) * 2000-07-05 2004-12-09 Saucy Gabriel G. Method of making teprenone
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
GEP20063908B (en) * 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
WO2003096548A2 (de) * 2002-05-14 2003-11-20 Siemens Aktiengesellschaft Verfahren zum erzeugen eines sendesignals
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ATE469645T1 (de) * 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004085448A2 (en) * 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
US20070021346A1 (en) * 2005-05-26 2007-01-25 Ewing William R N-terminally modified GLP-1 receptor modulators
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) * 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
WO2006017292A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AU2005269556B2 (en) 2004-07-27 2011-10-27 The Regents Of The University Of California Genetically modified host cells and use of same for producing isoprenoid compounds
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) * 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TWI373329B (en) * 2005-07-26 2012-10-01 Colgate Palmolive Co Toothbrush
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1951220A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2487154B1 (en) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20070238669A1 (en) * 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
CN102711739B (zh) 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
BR112012011274A2 (pt) 2009-11-13 2016-04-12 Astrazeneca Uk Ltd formulação de metformina de massa reduzida e sua combinação
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
RU2596787C2 (ru) 2010-07-09 2016-09-10 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
EP2600716A4 (en) 2010-08-03 2014-02-19 Beth Israel Hospital METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
TR201908247T4 (tr) 2012-11-20 2019-06-21 Lexicon Pharmaceuticals Inc Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
KR20210065974A (ko) 2018-09-26 2021-06-04 렉시컨 파마슈티컬스 인코퍼레이티드 N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
BR112023000808A2 (pt) 2020-07-29 2023-02-07 Amryt Pharmaceuticals Inc Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos

Also Published As

Publication number Publication date
DK8889D0 (da) 1989-01-10
HU203894B (en) 1991-10-28
JPH01213288A (ja) 1989-08-28
ZA8953B (en) 1989-10-25
AU615507B2 (en) 1991-10-03
HUT48900A (en) 1989-07-28
AU2832189A (en) 1989-07-13
EP0324421A2 (en) 1989-07-19
US4871721A (en) 1989-10-03
EP0324421A3 (en) 1990-08-22
NZ227303A (en) 1991-03-26

Similar Documents

Publication Publication Date Title
DK8889D0 (da) Phosphorholdige squalen-synthetase-inhibitorer, deres fremstilling og anvendelse, samt mellemprodukter og fremstilling deraf
DK316189D0 (da) Heteroaryloxy-n-isopropylanilider, fremgangsmaade til deres fremstilling samt deres anvendelse
DK345488A (da) Azolylmethyl-cyclopropyl-derivater, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK374389A (da) Arylbenzenoxazolidinoner, deres fremstilling og anvendelse
DK317088D0 (da) Substituerede triazolinoner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK300688D0 (da) Heterocycliske hydroxyethylazolderivater, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK88989D0 (da) Substituerede pyrimidiner, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse
DK494589D0 (da) Substituerede 1,3,5-triazintrioner og deres anvendelse samt mellemprodukter til deres fremstilling
DK358389D0 (da) 4-halogen-5-nitrothiazol-derivater, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK360189D0 (da) S-adenosyl-methionin-decarboxylase-inhibitorer, deres fremstilling og anvendelse
DK178589D0 (da) Triazoloaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK436388D0 (da) Substituerede pyrimidiner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK289287D0 (da) 1-phenylalkylimidazol-4- og/eller -5-carboxamider samt deres fremstiling og anvendelse
DK639888D0 (da) 3-aminopyrazolin-5-oner, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK196389D0 (da) N-substituerede n-amino-pyrroler, deres fremstilling og anvendelse
DK548086D0 (da) Nitroanthracycliner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK25989D0 (da) 4-alkyl-1,4-dihydropyridiner samt deres fremstilling og anvendelse
DK88889D0 (da) Substituerede imidazolinoner og -thioner, deres fremstilling og anvendelse samt mellemprodukter og disses fremstilling
DK630788D0 (da) N-substituerede dichlormaleinimider, fremgangsmaade til deres fremstiling samt deres anvendelse
DK259089A (da) Aminoguanidinoaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK355389A (da) Hydroxyalkynyl-azolylderivater, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DK378989D0 (da) Halogenvinylazolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse
DK264788D0 (da) Azolyl-tetrahydrofuran-2-yliden-methaner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK436588D0 (da) Substituerede pyridiner, fremgangsmaader til deres fremstilling samt deres anvendelse
DK355289A (da) 2,2-dihalogencyclopropyl-hydroxy-ethyltriazoler, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment